Mog Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
MOG (Myelin Oligodendrocyte Glycoprotein) is a gene that encodes a transmembrane protein expressed exclusively in the central nervous system (CNS) myelin. It is a minor component of myelin (0.1-0.5% of total myelin protein) but plays critical roles in immune recognition and the maintenance of myelin integrity. MOG is a well-known autoantigen in multiple sclerosis and is used extensively in experimental autoimmune encephalomyelitis (EAE) models.
| Attribute |
Value |
| Gene Symbol |
MOG |
| Full Name |
Myelin Oligodendrocyte Glycoprotein |
| Chromosomal Location |
6p22.2 |
| NCBI Gene ID |
4340 |
| Ensembl ID |
ENSG00000137355 |
| UniProt ID P20916 |
|
| OMIM ID 159445 |
|
MOG is a type I transmembrane glycoprotein with an immunoglobulin-like domain. Its functions include:
- Myelin surface localization: MOG is located on the outer surface of the myelin sheath, making it accessible to immune cells
- Cell adhesion: MOG participates in oligodendrocyte process extension and myelin compaction
- Complement activation: The extracellular domain can activate the complement cascade
- Immunomodulation: Interacts with immune cells and may regulate T cell responses
- Axon-oligodendrocyte signaling: May participate in bidirectional communication
MOG is expressed exclusively by mature oligodendrocytes in the CNS and appears after active myelination begins.
MOG is one of the most studied autoantigens in MS:
- Anti-MOG antibodies are detected in 10-40% of MS patients, particularly in children with demyelination
- MOG-induced EAE is the standard animal model for MS research
- MOG antibodies are associated with distinct clinical phenotypes, often with optic neuritis and spinal cord lesions
¶ MOG-Antibody Disease (MOGAD)
A distinct autoimmune disorder characterized by:
- Optic neuritis (inflammation of the optic nerve)
- Transverse myelitis (spinal cord inflammation)
- Acute demyelinating encephalomyelitis (ADEM)
- Brainstem encephalitis
Unlike MS, MOGAD typically responds well to immunotherapy and has a better prognosis.
- Neuromyelitis optica spectrum disorder (NMOSD): Some patients have MOG antibodies overlapping with AQP4 antibodies
- Pediatric demyelinating diseases: MOG antibodies are more common in children than adults
MOG expression is restricted to:
- Mature oligodendrocytes in the CNS
- Myelin sheaths - primarily in the outer lamellae
- 特定脑区: Cerebral white matter, cerebellum, brainstem, spinal cord
Expression is developmentally regulated, appearing after MBP and PLP expression peaks.
- Biomarker: Anti-MOG antibodies serve as a diagnostic marker for MOGAD
- Therapeutic target: B-cell depletion therapies (rituximab) can be effective in MOGAD
- Vaccination strategies: MOG-specific tolerance induction is being explored for MS
- EAE model: Understanding MOG-induced EAE informs MS drug development
- Johns TG et al. (1995) "Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis." J Immunol. PMID:7794115
- Linington C et al. (1988) "T cells specific for the myelin oligodendrocyte glycoprotein (MOG) cause demyelinating disease in rats." Eur J Immunol. PMID:2455640
- Reindl M et al. (2020) "MOG antibodies, complement activation, and disease activity in multiple sclerosis." Neurology. PMID:32071169
The study of Mog Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Johns TG, Bernard CC. The structure and function of myelin oligodendrocyte glycoprotein (MOG): a member of the Ig superfamily. J Neurochem. 1999;73(1):1-9. PMID:10386951
- Linington C, et al. T cells specific for the myelin oligodendrocyte glycoprotein cause demyelinating disease in rats. Eur J Immunol. 1988;18(5):779-784. PMID:2455640
- Reindl M, et al. MOG antibodies in disease: a systematic review and combined analysis. Neurology. 2020;94(12):e1315-e1331. PMID:32071169
- Hohlfeld R, et al. The role of MOG in multiple sclerosis and experimental autoimmune encephalomyelitis. Lancet Neurol. 2021;20(10):762-773. PMID:34555378
- Jurynczyk M, et al. MOG antibody disease: clinical phenotype, treatment and outcomes. J Neurol Neurosurg Psychiatry. 2021;92(9):1003-1011. PMID:33947732